A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants with Amyotrophic Lateral Sclerosis

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2021
This article has no abstract
Epistemonikos ID: fd3c921737993fada38776500bf8575c5bf63168
First added on: Apr 11, 2025